Citadel Advisors
TMDX icon

Citadel Advisors’s Transmedics TMDX Stock Holding History

Citadel Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.1M Buy
558,824
+497,223
+807% +$42.1M ﹤0.01% 1865
2026
Q1 		$6.12M Sell
61,601
-81,646
-57% -$10.6M ﹤0.01% 4015
2025
Q4 		$17.4M Buy
143,247
+18,330
+15% +$2.3M ﹤0.01% 2523
2025
Q3 		$14M Sell
124,917
-31,524
-20% -$3.69M ﹤0.01% 2772
2025
Q2 		$21M Sell
156,441
-453,248
-74% -$49.8M ﹤0.01% 2082
2025
Q1 		$41M Buy
609,689
+376,755
+162% +$25.9M 0.01% 1315
2024
Q4 		$14.5M Buy
+232,934
New +$21.7M ﹤0.01% 2530
2024
Q3 		– Sell
-78,134
Closed -$12M – 15257
2024
Q2 		$11.8M Sell
78,134
-93,700
-55% -$11.2M ﹤0.01% 2577
2024
Q1 		$12.7M Sell
171,834
-18,755
-10% -$1.55M ﹤0.01% 2615
2023
Q4 		$15M Buy
190,589
+78,969
+71% +$4.76M ﹤0.01% 2332
2023
Q3 		$6.11M Buy
111,620
+101,897
+1,048% +$7.34M ﹤0.01% 3345
2023
Q2 		$817K Sell
9,723
-77,300
-89% -$5.92M ﹤0.01% 6886
2023
Q1 		$6.59M Sell
87,023
-160,129
-65% -$11.1M ﹤0.01% 3364
2022
Q4 		$15.3M Buy
247,152
+104,965
+74% +$5.58M ﹤0.01% 2262
2022
Q3 		$5.93M Sell
142,187
-29,823
-17% -$1.3M ﹤0.01% 3587
2022
Q2 		$5.41M Buy
+172,010
New +$4.59M ﹤0.01% 3653
2022
Q1 		– Sell
-13,216
Closed -$237K – 14576
2021
Q4 		$254K Buy
13,216
+2,391
+22% +$59.9K ﹤0.01% 11317
2021
Q3 		$358K Sell
10,825
-65,909
-86% -$2.01M ﹤0.01% 10671
2021
Q2 		$2.55M Buy
76,734
+62,540
+441% +$1.73M ﹤0.01% 5986
2021
Q1 		$589K Buy
+14,194
New +$437K ﹤0.01% 9330
2020
Q4 		– Sell
-62,951
Closed -$932K – 11524
2020
Q3 		$868K Buy
+62,951
New +$1.08M ﹤0.01% 6285
2020
Q2 		– Sell
-11,351
Closed -$137K – 10501
2020
Q1 		$137K Sell
11,351
-4,009
-26% -$67.2K ﹤0.01% 8372
2019
Q4 		$292K Sell
15,360
-32,565
-68% -$598K ﹤0.01% 7627
2019
Q3 		$1.14M Buy
47,925
+3,735
+8% +$89.6K ﹤0.01% 5371
2019
Q2 		$1.28M Buy
+44,190
New +$1.21M ﹤0.01% 5299

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors's TMDX Position: Q2 2026 in Review

Citadel Advisors increased its Transmedics (TMDX) stake by 807% in Q2 2026, buying an estimated $42.1M and bringing the position to 558,824 shares worth $37.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Citadel Advisors first reported a position in TMDX in Q2 2019 and has held it in 25 quarters since. The position peaked at $41M in Q1 2025. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Citadel Advisors held 558,824 shares of Transmedics worth $37.1M as of Q2 2026.
  • Citadel Advisors bought 497,223 Transmedics shares in Q2 2026, an estimated $42.1M.
  • Transmedics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1865 holding.
  • Citadel Advisors first reported a position in Transmedics in Q2 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Transmedics position peaked at $41M in Q1 2025.
  • 374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.